Bionano Genomics (BNGO *) Stock Overview
Provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BNGO * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.00 |
| 52 Week High | US$93.96 |
| 52 Week Low | US$19.30 |
| Beta | 1.62 |
| 1 Month Change | 9.52% |
| 3 Month Change | 15.06% |
| 1 Year Change | -67.92% |
| 3 Year Change | -99.74% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNGO * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 7.0% | 0% | 0% |
| 1Y | -67.9% | 0% | 0% |
Return vs Industry: BNGO * underperformed the MX Life Sciences industry which returned 11.9% over the past year.
Return vs Market: BNGO * underperformed the MX Market which returned 16.8% over the past year.
Price Volatility
| BNGO * volatility | |
|---|---|
| BNGO * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BNGO *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine BNGO *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 96 | Al Luderer | bionano.com |
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules.
Bionano Genomics, Inc. Fundamentals Summary
| BNGO * fundamental statistics | |
|---|---|
| Market cap | Mex$238.48m |
| Earnings (TTM) | -Mex$547.86m |
| Revenue (TTM) | Mex$498.31m |
Is BNGO * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNGO * income statement (TTM) | |
|---|---|
| Revenue | US$28.74m |
| Cost of Revenue | US$15.24m |
| Gross Profit | US$13.50m |
| Other Expenses | US$45.10m |
| Earnings | -US$31.60m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.85 |
| Gross Margin | 46.97% |
| Net Profit Margin | -109.95% |
| Debt/Equity Ratio | 27.1% |
How did BNGO * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 19:48 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bionano Genomics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |